Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
McKinsey
Express Scripts
Merck
AstraZeneca

Last Updated: May 25, 2022

Teva Pharms Company Profile


✉ Email this page to a colleague

« Back to Dashboard

Summary for Teva Pharms
International Patents:18
US Patents:10
Tradenames:260
Ingredients:255
NDAs:312

Drugs and US Patents for Teva Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Usa PALIPERIDONE PALMITATE paliperidone palmitate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 211149-005 Jul 6, 2021 DISCN No No See Plans and Pricing See Plans and Pricing
Teva Pharms AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE amlodipine besylate; benazepril hydrochloride CAPSULE;ORAL 077179-001 May 18, 2007 DISCN No No See Plans and Pricing See Plans and Pricing
Teva Pharms Usa TENOFOVIR DISOPROXIL FUMARATE tenofovir disoproxil fumarate TABLET;ORAL 091612-004 Jan 26, 2018 AB RX No No See Plans and Pricing See Plans and Pricing
Teva Pharms Usa RABEPRAZOLE SODIUM rabeprazole sodium TABLET, DELAYED RELEASE;ORAL 076822-001 Nov 8, 2013 AB RX No No See Plans and Pricing See Plans and Pricing
Teva Pharms OLANZAPINE olanzapine TABLET;ORAL 076000-004 Oct 24, 2011 DISCN No No See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Teva Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Pharms Usa COPAXONE glatiramer acetate FOR SOLUTION;SUBCUTANEOUS 020622-001 Dec 20, 1996 6,620,847 See Plans and Pricing
Teva Pharms Usa COPAXONE glatiramer acetate FOR SOLUTION;SUBCUTANEOUS 020622-001 Dec 20, 1996 5,981,589 See Plans and Pricing
Teva Pharms Intl SYNRIBO omacetaxine mepesuccinate POWDER;SUBCUTANEOUS 203585-001 Oct 26, 2012 7,842,687 See Plans and Pricing
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 8,367,605 See Plans and Pricing
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 7,199,098 See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for TEVA PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe for Injection 3.5 mg/vial ➤ Subscribe 2016-10-26
➤ Subscribe Injection 40 mg/mL, 1 mL pre-filled syringe ➤ Subscribe 2014-01-29
➤ Subscribe for Injection 100 mcg/vial and 500 mcg/vial ➤ Subscribe 2015-04-14
➤ Subscribe Extended-release Capsule 15 mg and 30 mg ➤ Subscribe 2008-08-11
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03
➤ Subscribe Injection 40 mg/mL, 1 mL pre-filled syringe ➤ Subscribe 2014-02-26
➤ Subscribe for Injection 200 mcg/vial ➤ Subscribe 2015-05-01
Premature patent expirations for TEVA PHARMS

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
See Plans and Pricing See Plans and Pricing

Supplementary Protection Certificates for Teva Pharms Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1746976 C01746976/01 Switzerland See Plans and Pricing PRODUCT NAME: IRINOTECAN SUCROSOFAT; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65994 25.07.2017
1632232 PA2016042 Lithuania See Plans and Pricing PRODUCT NAME: RILPIVIRINO HIDROCHLORIDAS + EMTRICITABINAS + TENOFOVIRO ALAFENAMIDAS; REGISTRATION NO/DATE: EU/1/16/1112 20160621
0961612 C00961612/01 Switzerland See Plans and Pricing PRODUCT NAME: PACLITAXELUM-ALBUMINUM; REGISTRATION NO/DATE: SWISSMEDIC 63182 26.08.2014
1411900 2011C/016 Belgium See Plans and Pricing PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214
1663240 PA2016045 Lithuania See Plans and Pricing PRODUCT NAME: RILPIVIRINAS + TENOFOVIRO ALAFENAMIDAS; REGISTRATION NO/DATE: EU/1/16/1112 20160621
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
AstraZeneca
Colorcon
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.